Table 7Cost effectiveness results for new entrants from high prevalence countries with varying number of secondary cases

NMB at £20,000 per QALYNMB at £30,000 per QALY
TSTIGTTST/IGTTSTIGTTST/IGT
Pai et al 2008
0Dom-52-29Dom-92
0.25Dom-47-25Dom-26
0.5Dom-42-22Dom511
0.75Dom-37-18Dom1116
1Dom-32-15Dom1820
Diel et al 2010
0Ext Dom-52Ext DomExt Dom-9Ext Dom
0.25Ext Dom-48Ext DomExt Dom-3Ext Dom
0.5Ext Dom-43Ext DomExt Dom4Ext Dom
0.75Ext Dom-38Ext DomExt Dom10Ext Dom
1Ext Dom-33Ext DomExt Dom17Ext Dom

From: Appendix L, Health economic model - 2011

Cover of Tuberculosis
Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
NICE Clinical Guidelines, No. 117.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK).
Copyright © 2006, Royal College of Physicians of London. Updated text, Copyright © 2011, National Institute for Health and Clinical Excellence.

For 2006 original guideline text, no part of the content may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other issue of this publication) without the written permission of the Royal College of Physicians of London. Applications for the Royal College of Physicians of London's written permission to reproduce any part of this publication should be addressed to the publisher.

For 2011 updated text, the material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.